Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma
- PMID: 32164294
- PMCID: PMC7139663
- DOI: 10.3390/cancers12030643
Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma
Abstract
Medulloblastoma, the most common pediatric malignant brain tumor, continues to have a high rate of morbidity and mortality in childhood. Recent advances in cancer genomics, single-cell sequencing, and sophisticated tumor models have revolutionized the characterization and stratification of medulloblastoma. In this review, we discuss heterogeneity associated with four major subgroups of medulloblastoma (WNT, SHH, Group 3, and Group 4) on the molecular and cellular levels, including histological features, genetic and epigenetic alterations, proteomic landscape, cell-of-origin, tumor microenvironment, and therapeutic approaches. The intratumoral molecular heterogeneity and intertumoral cellular diversity clearly underlie the divergent biology and clinical behavior of these lesions and highlight the future role of precision treatment in this devastating brain tumor in children.
Keywords: clinical trials; genetic and epigenetic heterogeneity; intertumoral diversity; medulloblastoma; molecular subgroups.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



References
-
- Cho Y.J., Tsherniak A., Tamayo P., Santagata S., Ligon A., Greulich H., Berhoukim R., Amani V., Goumnerova L., Eberhart C.G., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 2011;29:1424–1430. doi: 10.1200/JCO.2010.28.5148. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources